World Media Directory · RSS · Email Newsletters

There were 521 press releases posted in the last 24 hours and 442,752 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
AIM ImmunoTech 宣布获得荷兰主管机构和伦理委员会的批准，开始一项评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi (durvalumab) 联合治疗胰腺癌的 1b/2 期研究

TO:

FROM:
Your Name:
Your Email:	Please check your email address!
Subject:
Message:
Confirmation code:	Please, do not fill this field.
Confirmation version code:	Please, do not change this field.
Javascript data:	Please, do not fill if your javascript is turned off.
Please type in the code you see in the image. Or click Send Email to generate another image instead.